Immunitybio is trading 4.19% down at $9.95 now, with biotech weakness the clearest available context for the decline. - No clear company-specific explanation for the October 6 decline surfaced in available coverage. - XBI fell 2.50% during the regular session amid broad sector pressure, while major U.S. indexes rose. - A Form 144 reported a proposed insider share sale, but does not establish it caused the move or was completed.